Clinical Trials Browser

Phase 1/2 × Dermatofibrosarcoma × Immune Checkpoint Inhibitors × Clear all

NCT03425279 2025-09-23

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Phase 1/2 Completed

Neoplasms, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous